Navigation Links
Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies
Date:6/7/2008

Data from five pivotal phase 3 studies presented at the American Diabetes

Association 68th Scientific Sessions

SAN FRANCISCO, June 7 /PRNewswire/ -- Results from five pivotal phase 3 studies of alogliptin were announced today at the American Diabetes Association (ADA) 68th Scientific Sessions by Takeda Global Research & Development Center, Inc. Alogliptin, which has been shown to be a highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4), is currently under investigation as an oral treatment for type 2 diabetes. Alogliptin administered once daily demonstrated statistically significant reductions in hemoglobin A1c (HbA1c) versus placebo as a monotherapy and as an add-on therapy with the major classes of type 2 diabetes medications: metformin, thiazolidinediones, insulin and sulfonylureas.

"Almost half the patients with type 2 diabetes are not at the American Diabetes Association recommended HbA1c goal of less than 7 percent, so it's important to have new treatment options that are both effective and well tolerated to potentially address the large number of patients who aren't adequately controlled," said Richard Pratley, MD, director of the Diabetes & Metabolism Translational Medicine Unit at the University of Vermont College of Medicine. "These clinical data show that alogliptin effectively reduces blood sugar in patients, alone or when used in combination with existing oral anti-diabetic treatments as well as insulin, increasing the range of treatment options for patients."

In the alogliptin monotherapy study, a significantly greater percentage of patients achieved HbA1c levels of less than or equal to 7 percent. Similar results were seen in the add-on to metformin, thiazolidinedione and sulfonylurea studies. Across all studies, patients achieved significant reductions in HbA1c, up to 0.80 percent, depending on the alogliptin dose and their treatment regimen. Greater HbA1c reductions were seen in patients with h
'/>"/>

SOURCE Takeda Global Research & Development
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
2. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
3. Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkins Lymphoma
4. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
5. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
6. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
7. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
8. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
9. Kosans Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
10. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
11. EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by Pharmacia & Upjohn ... agonist which effectively reduces intraocular pressure. As the ... (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... -- Perrigo Company plc ("Perrigo") (NYSE: PRGO ; TASE) ... leading OTC brands from GSK in an all cash ... clear demonstration of Perrigo,s unique ability to maximize brand ... 36 countries.  Perrigo Chairman, President and ... excited to complete this transaction, which clearly demonstrates our ...
(Date:8/28/2015)... Massachusetts y LONDRES, 28 de agosto ... AEX: PHIA) anunció hoy su participación en el  ... exhibirá sus soluciones cardiológicas más recientes y novedosas, ... Cardiovascular, que conectan a las personas y la ... de ayudar a diagnosticar, guiar los tratamientos y ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5
... Medical, Inc. (Solta) (Nasdaq: SLTM ), ... today announced that Medicis Technologies Corporation (formerly LipoSonix, ... has received U.S. Food and Drug Administration (FDA) ... indicated for non-invasive waist circumference reduction. The LipoSonix ...
... SPRING, Md., Oct. 24, 2011 The U.S. ... generic versions of Zyprexa (olanzapine tablets) and Zyprexa ... and bipolar disorder. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... and disabling brain disorder. About 1 percent of ...
Cached Medicine Technology:Solta Medical Reports FDA Clearance Received for Second Generation LipoSonix® System 2Solta Medical Reports FDA Clearance Received for Second Generation LipoSonix® System 3Solta Medical Reports FDA Clearance Received for Second Generation LipoSonix® System 4Solta Medical Reports FDA Clearance Received for Second Generation LipoSonix® System 5FDA Approves First Generic Olanzapine to Treat Schizophrenia, Bipolar Disorder 2FDA Approves First Generic Olanzapine to Treat Schizophrenia, Bipolar Disorder 3
(Date:8/30/2015)... Raton, Fl (PRWEB) , ... August 30, 2015 , ... ... InHealth Media. Nutritional Products International and InHealth media is a global sales and ... , “We are extremely pleased to continue our business relationship with Mr. Reid Eckert, ...
(Date:8/30/2015)... ... 30, 2015 , ... Nutritional Products International ( http://www.nutricompany.com ) ... Assistant to CEO Mitch Gould for Nutritional Products International. Through all methods ... Kathleen graduated from Florida State University with a Bachelor of Science in Business ...
(Date:8/29/2015)... ... ... Rio Salado College President Chris Bustamante announced on Aug. 19 ... Initiatives and Information Services. O’Shea, who has served Rio Salado for the last two ... through innovative technologies and strategies. , “I am very proud to be able to ...
(Date:8/29/2015)... ... August 30, 2015 , ... Electronic ... 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The simple fact ... handwritten signature. , Clinical trial sites can now use audio, video ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... inventors from Miller Place, N.Y. "I specialize in manual therapy, and my invention ... it can be used for additional muscle dysfunction throughout the body." , They ...
Breaking Medicine News(10 mins):Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2
... April 9 Healthcare,workers at Tri-City Medical Center ... State Mediation & Conciliation Service,confirmed that caregivers strongly ... union authorization cards., TCMC caregivers become members ... thousands of other healthcare workers who have achieved ...
... PARK RIDGE, Ill., April 9 A study published ... Clinical Nutrition(i) suggests,an association between high egg consumption and ... not provide an explanation.,The researchers, Djousse and Gaziano, analyzed ... physicians over a 20 year period., The fact ...
... protein it expresses may cause some cases of the disease ... change in one gene, called CHI3L1, can increase a person,s ... causes the gene to release high levels of a protein ... been associated with an increased risk of asthma in past ...
... YORK, April 9 Duane Reade Holdings, Inc. today,announced ... has resigned from the Company to assume a senior ... resignation,will be effective on April 17, 2008., The ... Marketing Officer,position and will move swiftly to identify another ...
... stopped. But it can be predicted, and new research from ... lead healthier lives as a result. , Researchers have developed ... bodys bones. It reveals that the speed of physical aging ... (OSS), this new marker can be used by doctors ...
... N.J., April 9 Defined Health has,announced ... its 8th annual Therapeutic,Insight conference. Therapeutic Insight ... - 30, 2008, at The Westin New ... and key opinion leaders will discuss relevant,pharma/biotech ...
Cached Medicine News:Health News:North County Caregivers Join United Healthcare Workers 2Health News:Statement by the American Egg Board and Egg Nutrition Center on AJCN Study on Egg Consumption 2Health News:Statement by the American Egg Board and Egg Nutrition Center on AJCN Study on Egg Consumption 3Health News:Researchers Find Gene Mutation That Increases Asthma Risk 2Health News:Researchers Find Gene Mutation That Increases Asthma Risk 3Health News:Duane Reade Holdings, Inc. Announces Resignation of Chief Marketing Officer 2Health News:How fast you'll age is written in the bones, TAU research finds 2Health News:Defined Health Announces Final Speaker Roster and Agenda for Therapeutic Insight 2008 2Health News:Defined Health Announces Final Speaker Roster and Agenda for Therapeutic Insight 2008 3
Inquire...
Remote Blower With Bag-In/Bag-Out Option...
Class II Type B1 Biological Safety Cabinet...
Built-in, motor-driven internal calibration mass for convenient Touch-key calibration. Also capable of touch-key calibration with external weights. Built-in RS232 Interface, Shimadzu WindowsDirect ...
Medicine Products: